Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus' lead candidate, TT-20, induces regeneration of myelin-producing oligodendrocytes, reverses white matter injury in an animal models of perinatal brain injury and multiple sclerosis and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 8 Davis Drive, Durham,nc 27709,united States
- Phone
- 919-491-4995
- Industry
- Biotechnology
- Website
- tellustherapeutics.com
- HQ
- Durham, NC
Tellus Therapeutics, Inc Questions
Tellus Therapeutics, Inc's helpline number is 919-491-4995
Tellus Therapeutics, Inc's website is tellustherapeutics.com
Tellus Therapeutics, Inc's LinkedIn profile is https://www.linkedin.com/company/tellus-therapeutics-inc
Tellus Therapeutics, Inc has
11 employees.
View email and phone details for 11
employees at Tellus Therapeutics, Inc.
Tellus Therapeutics, Inc's industry is
Biotechnology
Tellus Therapeutics, Inc's top competitors are
Grid Therapeutics,
Painqx,
Madera Therapeutics,
Kriya Therapeutics, Inc.,
Bambusa Therapeutics,
Glycan Therapeutics,
Precision Biosciences, Inc.,
Xontogeny,
Oncoc4, Inc.,
Opus Genetics.
Tellus Therapeutics, Inc's categories are Biotechnology
Tellus Therapeutics, Inc's founding year is 2018
